Evidence map›Paper›PMID 42587039›Full record

ArticleExperimental & molecular medicine2026

Meloxicam protects against muscle and metabolic decline in ageing through Cdon restoration and oxidative stress modulation.

Ju-Hyeon Bae, Hyun-Kyung So, Yideul Jeong, Jeongmin Park, June Kim, Tae Young Kim, Young-Eun Leem, Tuan Anh Vuong, Jiwoong Jang, Moongi Ji and 6 more

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ju-Hyeon Bae *Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
Hyun-Kyung So *Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
Yideul JeongResearch Institute of Aging Related Disease, AniMusCure Inc., Suwon, 16419, Republic of Korea.
Jeongmin ParkDepartment of Metabiohealth, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
June KimDepartment of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
Tae Young KimDrug Information Research Institute, Muscle Physiome Research Center, College of Pharmacy, Sookmyung Women's University, Seoul, 04310, Republic of Korea.
Young-Eun LeemDepartment of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
Tuan Anh VuongResearch Institute of Aging Related Disease, AniMusCure Inc., Suwon, 16419, Republic of Korea.
Jiwoong JangDepartment of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute Gachon University School of Medicine, Incheon, 21999, Republic of Korea.
Moongi JiCollege of Pharmacy, Sunchon National University, Suncheon, 57922, Republic of Korea.
Hyon-Seung YiDepartment of Medical Science, Chungnam National University, Daejeon, 34134, Korea.
Il-Young KimDepartment of Molecular Medicine, Lee Gil Ya Cancer and Diabetes Institute Gachon University School of Medicine, Incheon, 21999, Republic of Korea.ORCID http://orcid.org/0000-0002-6314-2415
Man-Jeong PaikCollege of Pharmacy, Sunchon National University, Suncheon, 57922, Republic of Korea.
Sang-Jin LeeResearch Institute of Aging Related Disease, AniMusCure Inc., Suwon, 16419, Republic of Korea.ORCID http://orcid.org/0000-0002-6286-3894
Gyu-Un BaeResearch Institute of Aging Related Disease, AniMusCure Inc., Suwon, 16419, Republic of Korea. gbae@sookmyung.ac.kr.
Jong-Sun KangDepartment of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea. kangj01@skku.edu.

Funding

Korea Health Industry Development Institute (KHIDI) RS-2024-00507183National Research Foundation of Korea (NRF) RS-2022-NR070845National Research Foundation of Korea (NRF) RS-2025-00516722
6 · The paper itself

Abstract

Sarcopenia is characterized by progressive decline in skeletal muscle mass and function, driven in part by impaired mitochondrial homeostasis and redox imbalance. However, the upstream regulators that integrate metabolic resilience with muscle integrity during ageing remain poorly defined. Here, we identify the cell adhesion molecule Cdon as a conserved determinant of adult muscle maintenance whose expression declines with human aging, sarcopenia and muscle-wasting disease. Reduced Cdon expression was associated with transcriptional atrophy signatures, metabolic insufficiency and reduced myofibre size. Using a Cdon promoter-based screen, we identified meloxicam (Mcam) as a small molecule inducer of Cdon that enhances myogenic differentiation, increases muscle mass and function in young mice and mitigates age-related muscle atrophy. Mcam treatment also improved neuromuscular conduction and systemic metabolic parameters, including blood glucose regulation and hepatic lipid accumulation. In aged muscle, Mcam normalized cysteine accumulation, restored redox balance, improved mitochondrial metabolism and reduced oxidative stress. Mechanistically, Mcam activated Ampk signalling to preserve Cdon expression under oxidative challenge and support antioxidant and mitochondrial quality control pathways. Together, these findings identify Cdon decline as a hallmark of muscle ageing and demonstrate that Mcam preserves muscle integrity by reestablishing redox and metabolic homeostasis through Ampk-dependent maintenance of Cdon. Age-related decline of Cdon is a key molecular feature of skeletal muscle dysfunction. In this study, meloxicam restored Cdon expression through Ampk activation, thereby preserving muscle integrity and functional capacity in aged muscle. Mechanistically, meloxicam normalized cysteine metabolism and elevates Gpx4 expression, improving glutathione buffering and suppressing excessive reactive oxygen species accumulation. Activation of the Ampk-Cdon axis was associated with maintenance of mitochondrial homeostasis and redox balance. Together, these findings identify Cdon as a potential therapeutic target for age-associated skeletal muscle degeneration.

Indexed as

AgingCell Adhesion MoleculesMeloxicamMuscle, SkeletalOxidative StressAnimalsHumansMiceMitochondriaOxidation-ReductionSarcopeniaCell Adhesion MoleculesMeloxicam

Identifiers

PMID42587039
PMCPMC13538359

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.